Autism Epidemic Linked to Epidemic of Vaccine Induced Diabetes

BALTIMORE, July 12, 2013 /PRNewswire/ -- The following release was issued by Classen Immunotherapies, Inc.

A new peer reviewed study was published in the current issue of Open Access, Scientific Reports (Volume 2, Issue 3, 2013)  linking the autism epidemic to the epidemic of  vaccine induced type 1 diabetes. Growing evidence shows that a large percentage of cases of autism have an inflammatory or autoimmune component. The new data shows autism is strongly linked to type 1 diabetes another epidemic inflammatory disease where the epidemic has been proven to be caused by vaccines. The new paper is authored by immunologist J. Bart Classen, MD.

"We have been publishing for many years that vaccine induced inflammation is causing an epidemic of type 1 diabetes and other diseases. Our new data, as well as the extensive data from others regarding the role of inflammation in the development autism, leaves little doubt vaccines play a significant role in the autism epidemic," says Dr. J. Bart Classen, MD.

Dr. Classen's research indicates that the large number of vaccines given to patients is leading to an epidemic of chronic inflammation resulting in epidemics of autoimmune diseases, allergies, and a comprehensive inhibitory response manifesting as obesity and metabolic syndrome. 

"The best data indicates that vaccine induced chronic disease is now of a magnitude that dwarfs almost all prior poisoning of humans including poisoning from agents like asbestos, low dose radiation, lead and even cigarettes. Most patients don't even realize that they are suffering from the adverse effects of vaccines. Even more concerning patients and or their parents are being harassed, accused of practicing poor dieting and exercise habits leading to development obesity and diabetes when in fact they suffer from vaccine induced obesity and diabetes," says Dr. J. Bart Classen.

Copies of many of Dr. Classen's papers can be found on the website www.vaccines.net. 

Classen Immunotherapies, Inc.
410 377 8526
[email protected]

SOURCE Classen Immunotherapies, Inc.